Oxford-based The Native Antigen Company (NAC) has received new investment from the Mercia Growth Fund 1 and NAC’s existing shareholders.
The new investment will accelerate the continued expansion of this now profitable operation which seeks to expand into key markets within the in vitro diagnostic (IVD) and pharmaceutical sectors.
NAC specialises in the isolation and purification of native viral and bacterial antigens which are needed to provide the high levels of the specificity and sensitivity required by the latest generation of serology based IVD tests. It is also pioneering into the use of mammalian cell expression platforms, with an emphasis on producing antigens for use in vaccine development.
The company’s success will be showcased at Mercia Fund Management‘s (MFM) first Open House event for companies seeking seed and expansion funding on 16 April 2013.
Original Mercia announcement
Posted on Tuesday 2nd April 2013